相关实验视频

Updated: Jun 19, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

局部晚期宫癌:新辅助治疗与标准放射化疗相比 - - 一个更新的元分析

Carlo Ronsini¹, Maria Cristina Solazzo¹, Eleonora Braca¹

¹Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

|July 27, 2024

概括

在并发化疗或新辅助化疗后增加手术显著改善了局部晚期宫癌患者的无病生存率和整体生存率. 这一元分析支持外科手术作为有益的治疗升级.

科学领域:

妇科瘤学妇科瘤学
辐射瘤学辐射瘤学
手术瘤学手术瘤学

背景情况:

随着或不随着支臂疗法进行的绝对并发化疗 (CCRT) 是局部晚期宫癌 (LACC) 的标准.
在LACC的新辅助治疗后,辅助手术的作用仍然是争论的主题.
这一元分析评估了新辅助治疗后手术的疗效,与标准治疗方案相比.

研究的目的:

为了比较经过新辅助治疗后接受手术的LACC患者的生存结果,与接受标准治疗的患者相比.
提供关于辅助手术在LACC管理中的有争议作用的最新视角.

主要方法:

在2023年4月,在PubMed和Embase上进行了系统的文献搜索,遵守PRISMA指南.
包括的研究是比较性的,重点是无病生存 (DFS) 和整体生存 (OS).
没有应用任何地理或语言限制,尽管只考虑了英语文章.

主要成果:

与单独使用CCRT相比,CCRT加上手术显著改善了DFS和OS.
与CCRT相比,经过手术后的新辅助化疗 (NACT) 显著改善了DFS和OS.
随机对照试验的子分析表明,与CCRT相比,手术改善了DFS和OS的非显著趋势.

结论:

与标准治疗方法相比,经过子宫切除后的新辅助疗法在LACC患者中显著增强了DFS和OS.
这些发现支持在CCRT或NACT后考虑切除子宫,以改善患者的治疗结果.
最新证据表明,手术干预可能是LACC治疗范例中一个有价值的组成部分.

关键词:

局部晚期的宫癌.新辅助治疗新辅助治疗癌症结局的结果.无线电化疗是无线电化疗的一种疗法.

更多相关视频

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...